Figure 2
![Figure 2. Duration of CHR and MCyR with bosutinib treatment. Duration of CHR (A) and MCyR (B) were determined by the evaluable population; patients entering the study in CCyR were excluded. As of the data cutoff, 77% of the evaluable patients who achieved a CHR still retained their response (124/172 [72%] imatinib-resistant and 65/75 [87%] imatinib-intolerant patients), with a median duration of CHR not reached. Of the evaluable patients who achieved a MCyR, 78% still retained their MCyR as of the data cutoff (73/101 [72%] imatinib-resistant and 36/39 [92%] imatinib-intolerant patients), with the median duration of MCyR not reached.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/17/10.1182_blood-2011-05-355594/4/zh89991179890002.jpeg?Expires=1723675247&Signature=VQpClOtoaDLzY4WQysbI-~SukPvbusGQNieIW-nbnnhv0FU6At1y0QT7ZuVupInmEecXcKZh~-1LM2M5EAI4fgtV~ai6N3MxNVmDCA0OZ~X4Z0XVWSbNAIyvQj~94gCFxESRGPanFDd~Tm2SO87W76RzuqlKb9ZQ~0yvO2mYEP6eQ-gLuNv0c1n2rjpkcr8R6qSIUInoaIKecp026B7SD75tRkEOs4ERwbcVXM~QRWsDKQPciLJ0Eyj79KruHIGCSLdOVMX~~BnILlxVPQdGOH6TwhaJvmJowmq6Ps2v1Rokv4T6JHKnZxePfIghlEAQpQSHkd-AzbF~0hnqJ5h~FA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Duration of CHR and MCyR with bosutinib treatment. Duration of CHR (A) and MCyR (B) were determined by the evaluable population; patients entering the study in CCyR were excluded. As of the data cutoff, 77% of the evaluable patients who achieved a CHR still retained their response (124/172 [72%] imatinib-resistant and 65/75 [87%] imatinib-intolerant patients), with a median duration of CHR not reached. Of the evaluable patients who achieved a MCyR, 78% still retained their MCyR as of the data cutoff (73/101 [72%] imatinib-resistant and 36/39 [92%] imatinib-intolerant patients), with the median duration of MCyR not reached.
